Substance Abuse - Epidemiology Forecast to 2027

Substance Abuse - Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Substance (Drug) Abuse - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Substance (Drug) Abuse epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Substance (Drug) Abuse Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Substance (Drug) Abuse in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Substance (Drug) Abuse outlook. It also includes the explanation of changing trends of epidemiology outlining the Substance (Drug) Abuse scenario.

Substance (Drug) Abuse Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Substance (Drug) Abuse thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Substance (Drug) Abuse explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Substance (Drug) Abuse Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Substance (Drug) Abuse

Key assessments
• Patient Segmentation in Substance (Drug) Abuse
• Substance (Drug) Abuse Risk & Burden
• Factors driving growth in a specific Substance (Drug) Abuse patient population
1. Report Introduction
2. Substance (Drug) Abuse Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Substance (Drug) Abuse in 2017
2.2. Patient Share Distribution of Substance (Drug) Abuse in 2027
3. Disease Background and Overview: Substance (Drug) Abuse
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Substance (Drug) Abuse in 7MM
4.3. Total Prevalent/ Incident Patient Population of Substance (Drug) Abuse in 7MM – By Countries
5. Epidemiology of Substance (Drug) Abuse by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.1.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.1.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.1.5. Diagnosed Cases of the Substance (Drug) Abuse
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.4.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.4.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.4.5. Diagnosed Cases of the Substance (Drug) Abuse
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.5.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.5.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.5.5. Diagnosed Cases of the Substance (Drug) Abuse
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.6.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.6.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.6.5. Diagnosed Cases of the Substance (Drug) Abuse
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.7.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.7.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.7.5. Diagnosed Cases of the Substance (Drug) Abuse
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.8.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.8.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.8.5. Diagnosed Cases of the Substance (Drug) Abuse
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Substance (Drug) Abuse
5.9.3. Sub-Type Specific cases of the Substance (Drug) Abuse *
5.9.4. Sex- Specific Cases of the Substance (Drug) Abuse *
5.9.5. Diagnosed Cases of the Substance (Drug) Abuse
6. Unmet Needs of the Substance (Drug) Abuse
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Substance (Drug) Abuse in 7MM
Table 2: Total Prevalent/Incident Cases of the Substance (Drug) Abuse in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Substance (Drug) Abuse in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Substance (Drug) Abuse in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Substance (Drug) Abuse in United States (2016-2027)*
Table 6: Diagnosed Cases of the Substance (Drug) Abuse in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Substance (Drug) Abuse in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Substance (Drug) Abuse in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Substance (Drug) Abuse in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Substance (Drug) Abuse in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Substance (Drug) Abuse in France (2016-2027)
Table 12: Sub-Type Specific cases of the Substance (Drug) Abuse in France (2016-2027) *
Table 13: Sex- Specific Cases of the Substance (Drug) Abuse in France (2016-2027) *
Table 14: Diagnosed Cases of the Substance (Drug) Abuse in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Substance (Drug) Abuse in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Substance (Drug) Abuse in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Substance (Drug) Abuse in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Substance (Drug) Abuse in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Substance (Drug) Abuse in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Substance (Drug) Abuse in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Substance (Drug) Abuse in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Substance (Drug) Abuse in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Substance (Drug) Abuse in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Substance (Drug) Abuse in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Substance (Drug) Abuse in UK (2016-2027) *
Table 26: Diagnosed Cases of the Substance (Drug) Abuse in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Substance (Drug) Abuse in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Substance (Drug) Abuse in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Substance (Drug) Abuse in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Substance (Drug) Abuse in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us